Table 4.

Haplotype analyses of glioma risk

GeneHaplotypeFrequency
OR (95% CI)*Global score test
TotalCasesControls
XPC0.281
C C0.3940.3870.4011.00 (reference)
C A0.3700.3870.3531.16 (0.92-1.48)
T A0.2350.2250.2460.95 (0.72-1.23)
XPD0.025
T T0.4230.4220.4291.00 (reference)
G G0.3400.3700.3071.20 (0.94-1.54)
G T0.2120.1930.2320.86 (0.65-1.15)
T G0.0250.0150.0320.40 (0.17-0.98)
XRCC10.071
C T0.5630.5420.5841.00 (reference)
C A0.3600.3830.3361.28 (1.03-1.59)
T T0.0770.0740.0791.05 (0.66-1.69)
MGMT0.280
C A A0.7740.7880.7591.00 (reference)
T A A0.1130.0970.1280.77 (0.54-1.08)
C G G0.1030.1070.0991.09 (0.76-1.54)
T G G0.0100.0070.0130.56 (0.11-2.78)
LIG10.120
C C0.4760.4850.4661.00 (reference)
C A0.3820.3910.3721.03 (0.82-1.31)
T A0.1230.1120.1350.75 (0.53-1.08)
T C0.0190.0120.0270.51 (0.17-1.49)
  • NOTE: Loci chosen for XPC, W499R and K939Q; XPD, R156R and Q751K; XRCC1, W194I and R399Q; MGMT, F84L, V143I, and R178K; LIG1, 5′UTR and A170A.

  • * Adjusted for age and gender.

  • Generated by permutation test with 1,000 times.